Primary EV-301 Results Confirm Enfortumab Vedotin’s Superiority Over Chemotherapy in Advanced Urothelial Carcinoma
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium
HIF-2α Inhibitor/Cabozantinib Doublet Active in Previously Treated Advanced ccRCC
Choueiri et al tested the efficacy of the investigational hypoxia-inducible factor 2α (HIF-2α) inhibitor in combination with cabozantinib.
Real-World Data: Cabozantinib Used More Commonly Than Other TKIs After Checkpoint Inhibition in mRCC
Investigators of this retrospective observational cohort study evaluated outcomes with cabozantinib or other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma (RCC) following immune checkpoint inhibition.
Final TITAN Analysis Confirms Superior OS Benefit With Apalutamide and ADT Versus ADT Alone
The final analysis of the phase 3 TITAN trial included nearly 4 years of follow-up.
Nivolumab, Docetaxel, and ADT Triplet Confers Antitumor Activity in mCRPC Regardless of Prior NAT Use
Karim Fizazi, MD, PhD, presents final analysis results from arm B of the phase 2 CheckMate 9KD trial.
Reduced PSA Screening Correlates With Uptick in Metastatic Prostate Cancer Presentation at Diagnosis
Sharma et al investigated whether reductions in prostate-specific antigen (PSA) screening were responsible for increased metastatic prostate cancer diagnoses in the United States.
Nivolumab/Cabozantinib Prolongs OS in Advanced RCC With Sarcomatoid Features
CheckMate 9ER investigators assessed the efficacy of combination nivolumab and cabozantinib in the front-line sarcomatoid renal cell carcinoma (RCC) setting in an extended analysis.
Adjuvant Nivolumab Improves DFS in MIUC After Radical Surgery
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.
Survival Trends Analysis Shows Significant OS Gains for MIBC, But Not Urothelial Carcinoma
Investigators of this real-world analysis studied survival trends among patients with muscle-invasive bladder cancer (MIBC) and patients with metastatic urothelial carcinoma (UC).
Percent Decline in PSA May Predict Survival in Enzalutamide-Treated nmCRPC
The percent decline and actual decline in PSA levels in men with nonmetastatic castration-resistant prostate cancer treated with androgen deprivation therapy and enzalutamide are associated with the risk for death and metastasis, a study found.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GU 2021
Loading... 
Loading...